WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Russia sentences Pussy Riot activist to six years in absentia for Ukraine "war fakes"HKFP Lens: Hong Kong marks China's National Day with displays of patriotism, pyrotechnicsBiden administration imposes firstYang Hengjun: Australian writer detained in China fears he will die in jailChris Hipkins says sick children shouldn't be at schoolChanges to flu vaccine eligibility missed opportunity to improve health equityBuildings shake briefly as earthquake rattles TaiwanFour killed, several injured as race car hits spectators at Hungary rallyTruth Social: Trump's DJT stock plummets days after going publicHow homeowners are responding to huge insurance premium hikes